cyclin-dependent kinase


Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.

cyclin-dependent kinase

[¦sī·klin di¦pen·dənt ′kī‚nās]
(cell and molecular biology)
A family of kinases that, once activated by cyclin, regulate the cell cycle by adding phosphate groups to a variety of protein substrates that control processes in the cycle. Abbreviated Cdk.
References in periodicals archive ?
Sharma, "Cyclin-dependent kinase 5/p35/p39: a novel and imminent therapeutic target for diabetes mellitus," International Journal of Endocrinology, vol.
Squires et al., "A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors," Annals of Oncology, vol.
p21WAF1 (p21) and p27KIP1 (p27) are both universal inhibitors of cyclin-dependent kinases and can therefore influence cell cycle or tumor progression.
Pines, "Cyclin-dependent kinase inhibitors: the age of crystals," Biochimica et Biophysica Acta--Reviews on Cancer, vol.
It is well known that cyclin-dependent kinase (CDK) 4, CDK6, and cyclin D play crucial roles in the regulation of cell cycle progression from the G1 to S phase [12].
MJ-29 inhibits tubulin polymerization, induces mitotic arrest, and triggers apoptosis via cyclin-dependent kinase 1-mediated Bcl-2 phosphorylation in human leukemia U937 cells.
Cyclin D1 regulates G1 phase progression via cyclin-dependent kinase 4/6-dependent phosphorylation and partial inactivation of the repressive activity of the retinoblastoma protein.
GW8510 inhibits the enzyme cyclin-dependent kinase 2, which helps trigger cell division and attracts chemotherapy drugs.
Where indicated, patients must have received endocrine therapy with or without a cyclin-dependent kinase 4/6 inhibitor.
Syros Pharmaceuticals announced that data from the dose escalation portion of its Phase 1 trial of SY-1365, its first-in-class selective cyclin-dependent kinase 7 inhibitor, demonstrated proof-of-mechanism at tolerable doses in patients with advanced solid tumors.
Eli Lilly and Company today announced that its Phase 3 JUNIPER study evaluating Verzenio (abemaciclib), a cyclin-dependent kinase (CDK)4 and CDK6 inhibitor, as monotherapy in KRAS-mutated, advanced non-small lung cancer (NSCLC) did not meet its primary endpoint of overall survival (OS).